Exploratory IND Concept Needs Expansion, Merck Exec Says
Executive Summary
FDA should expand its "Exploratory IND" guidance to make it easier for manufacturers to do pilot studies involving radioactive tracers, Merck Division of Imaging Senior Director David Mozley told a May 5 meeting on "Critical Path" opportunities cosponsored by FDA, the Biotechnology Industry Organization and the Drug Information Association in Bethesda, Md
You may also be interested in...
PhRMA, BIO Question Impact Of Exploratory INDs On Patent Restoration
Industry stakeholders are questioning the potential impact of exploratory investigational new drug applications on Waxman/Hatch patent restoration provisions
PhRMA, BIO Question Impact Of Exploratory INDs On Patent Restoration
Industry stakeholders are questioning the potential impact of exploratory investigational new drug applications on Waxman/Hatch patent restoration provisions
Exploratory INDs Will Better Serve Large Companies, PDL Exec Says
Exploratory investigational new drug applications will provide a greater benefit to large pharma and biotech companies, Protein Design Labs CEO Mark McDade said at the Biotechnology Industry Organization Windhover conference in Washington, D.C. April 26